Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Non-Current Deffered Revenue: 2015-2018

Historic Non-Current Deffered Revenue for Viking Therapeutics (VKTX) over the last 3 years, with Dec 2018 value amounting to $12,000.

  • Viking Therapeutics' Non-Current Deffered Revenue was N/A to $12,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $12,000, marking a year-over-year change of. This contributed to the annual value of $12,000 for FY2018, which is N/A change from last year.
  • Viking Therapeutics' Non-Current Deffered Revenue amounted to $12,000 in FY2018, which was down 26.41% from $16,307 recorded in FY2016.
  • Viking Therapeutics' 5-year Non-Current Deffered Revenue high stood at $31,239 for FY2015, and its period low was $12,000 during FY2018.
  • For the 2-year period, Viking Therapeutics' Non-Current Deffered Revenue averaged around $14,154, with its median value being $14,154 (2016).
  • Data for Viking Therapeutics' Non-Current Deffered Revenue shows a maximum YoY crashed of 47.80% (in 2016) over the last 5 years.
  • Viking Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $31,239 in 2015, then slumped by 47.80% to $16,307 in 2016, then reached $12,000 in 2018.